The AHA appreciates the Medicare Payment Advisory Commission’s concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing. “Hospitals, and the clinicians who work in them, know firsthand the lifesaving potential of drug therapies … however, an unaffordable drug is not a lifesaving drug,” AHA said in a letter to MedPAC commissioners. AHA shared recommendations with MedPAC, including mandating an average sales price inflation cap for Medicare Part B and Part D drugs, and applying the cap to both high-cost and lower-cost drugs; identifying approaches to preventing excessively high launch prices as a response to an ASP inflation cap; maintaining the ASP plus 6 percent payment methodology for Part B drugs; testing a new Part D payment model that reduces or eliminates reinsurance payments while making appropriate adjustments to the direct subsidy rate; and improving annual public reports on Medicare Part B and Part D drug costs by making them more consumer and provider-friendly.

Related News Articles

The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
The House Ways and Means Committee today launched a health task force to better address the needs of residents in rural and underserved communities.
In this AHA Stat Blog, Jay Bhatt, senior vice president and chief medical officer of the AHA, looks at last year’s Innovation Challenge winners and how they…
The AHA and the Department of Homeland Security July 17 at 1 p.m. ET will host a webinar discussing current cybersecurity threats to the health care sector.
Chairperson's File
Hospitals and health systems are tackling affordability head on. AHA’s The Value Initiative has been leading the charge — developing new resources, sharing…
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…